Latest News

  • Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia Read More
  • Alkermes plc Reports Second Quarter 2016 Financial Results Read More
  • Alkermes to Host Conference Call to Discuss Second Quarter 2016 Financial Results Read More

Investors

Learn more Learn More Alkermes PLC Investor Relations

Working at Alkermes

Join Our Team Join Our Team Working at Alkermes